Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
So found a study of more than 1,500 people treated for hep C, including almost 600 people with compensated advanced chronic liver disease.
Curing hep C slashes risk of death for those with liver cancer history
Currently, there are no pharmacological treatments for liver fibrosis related to non-alcoholic steatohepatitis.
Smoking cessation, a healthy diet, exercise and weight loss could dramatically reduce new liver cancer cases and liver disease deaths.
Hepatitis B and C, non-alcoholic steatohepatitis (NASH) and alcohol-related liver disease are the main causes of liver cancer and cirrhosis.
Women with a history of the malignancy also survive longer than men after receiving a liver transplant.
Primary biliary cholangitis (PBC) is a chronic liver disease resulting from the destruction of the bile ducts in the liver.
Sustained response to direct-acting antivirals prolonged survival by a year and a half.
People treated with Viread, Vemlidy or Baraclude are less likely to develop this malignancy.
This finding from a recent study applies to those who do not have cirrhosis when they are treated for the virus.
Opdivo plus Yervoy led to higher response rates and longer survival than Opdivo alone.
A new classification system may more accurately reflect liver-related death trends in the United States.
A new study shows that people with the liver disease have substantial financial burden that can impact their care.
The tool relies on 14 clinical variables, such as liver enzymes, body mass index, triglycerides, height and sex.
This could provide a safer, simpler alternative to the invasive surgical biopsies used to diagnosis liver disease.
We all had one heart going into the event: Honoring organ, eye, and tissue transplant donors, their families, and also recipients.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.